Reported 2 days ago
Piper Sandler has increased its price target for Amgen Inc. (NASDAQ:AMGN) from $328 to $342, while maintaining an Overweight rating. This adjustment follows the company's recent quarterly results, indicating that Amgen is well-prepared to handle the loss of exclusivity for denosumab, and is benefiting from strong performance across its commercial offerings and pipeline advancements.
Source: YAHOO